Innovative “Visible” Anti-Cancer Treatment with Radiopharmaceuticals

menu

Japanese

Himawari Venture Development Fund Grant Awarded

2022.07.29

We received a subsidy for the first half of the fiscal year 2022 from the Himawari Venture Development Fund.

R&D content [Commercialization of an Innovative “Visible” Cancer Treatment Method Using Radiotherapeutic Drugs from Chiba Prefecture]

Click here for details

Latest posts

2024.08.23
LinqMed received the “University Venture Award Special Prize” at the University Venture Award 2024
2024.05.24
An abstract of ASCO2024
2024.02.14
LinqMed was featured in Yomiuri Shimbun Online
2023.12.22
Announcement of selection for NEDO “The Deep-Tech Startup Support Fund/Deep-Tech Startup Support Program”
2023.12.22
LinqMed Announces Series A and additional Financing
2023.12.22
LinqMed and PeptiDream Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM in Japan
2023.11.15
Article published in the Japan Economic Research Institute “JERI Monthly Report”
2023.03.22
Received Venture Club Chiba 39th Business Plan Presentation Business Challenge Contest to Support Tomorrow’s Chiba Grand Award
2023.01.30
7th National Research and Development Agency Innovation Strategy Conference Panelist
2023.01.27
Mirai X (mirai cross) 2023 Category Grand Prize and GAP Grant Award